|
Título:
|
Global assessment of the impact of type 2 diabetes on sleep through specific questionnaires. A case-control study
|
|
Autor/a:
|
Lecube Torelló, Albert; Sánchez Peña, Enric; Gómez Peralta, Fernando; Abreu, Cristina; Valls Marsal, Joan; Mestre, Olga; Romero, Odile; Martínez González, María Dolores; Sampol, Gabriel; Ciudin, Andreea; Hernández, Cristina; Simó, Rafael
|
|
Notas:
|
Type 2 diabetes (T2D) is an independent risk factor for sleep breathing disorders. However,
it is unknown whether T2D affects daily somnolence and quality of sleep independently of
the impairment of polysomnographic parameters.
Material and Methods
A case-control study including 413 patients with T2D and 413 non-diabetic subjects, matched
by age, gender, BMI, and waist and neck circumferences. A polysomnography was performed
and daytime sleepiness was evaluated using the Epworth Sleepiness Scale (ESS). In addition,
135 subjects with T2D and 45 controls matched by the same previous parameters were
also evaluated through the Pittsburgh Sleep Quality Index (PSQI) to calculate sleep quality.
Results
Daytime sleepiness was higher in T2D than in control subjects (p = 0.003), with 23.9% of subjects
presenting an excessive daytime sleepiness (ESS>10). Patients with fasting plasma
glucose (FPG 13.1 mmol/l) were identified as the group with a higher risk associated with
an ESS>10 (OR 3.9, 95%CI 1.8–7.9, p = 0.0003). A stepwise regression analyses showed
that the presence of T2D, baseline glucose levels and gender but not polysomnographic parameters (i.e apnea-hyoapnea index or sleeping time spent with oxigen saturation lower
than 90%) independently predicted the ESS score. In addition, subjects with T2D showed
higher sleep disturbances [PSQI: 7.0 (1.0–18.0) vs. 4 (0.0–12.0), p<0.001].
Conclusion
The presence of T2D and high levels of FPG are independent risk factors for daytime
sleepiness and adversely affect sleep quality. Prospective studies addressed to demonstrate
whether glycemia optimization could improve the sleep quality in T2D patients
seem warranted.
This work was supported by grants from de Instituto de Salud Carlos III ISCIII (Fondo de Investigación Sanitaria, FI12/00803), European Union (European Regional Development Fund, Fondo Europeo de Desarrollo Regional, FEDER, “Una manera de hacer Europa”), and Fundación Sociedad Española Endocrinología y Nutrición (FSEEN). CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and CIBER de Enfermedades Respiratorias (CIBERES) are an initiative of the Instituto Carlos III. |
|
Derechos:
|
cc-by (c) Lecube Torelló, Albert et al., 2016
http://creativecommons.org/licenses/by/3.0/es/
|
|
Tipo de documento:
|
article
publishedVersion |
|
Editor:
|
Public Library of Science
|
|
Compartir:
|
|
